Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias.

摘要

Tigecycline is a broad-spectrum antibiotic with a high degree of activity against multi-drug resistant {MDR) Gram-negative bacilli and Gram-positive cocci. Published experience with tigecycline therapy of bacteremias is limited. Eight episodes of Gram-negative bacteremias (3 MDR Kfebsiella pneumoni-ae, 3 non-MDR K. prteumoniae, 1 Proteus mirabihs, 1 Enterobacter agglomerans) and one episode of Gram-positive bacteremia (Gemelia mor-billorum) which were successfully treated with tigecycline are described. Most (6/9) of the bacteremic episodes were treated with once-daily tigecycline 100 mg (i.v.) q24h. Because the serum half life (t_(1/2)) of tigecycline is 42 hours, on a pharmacokinetic basis, tigecycline once-daily dosing would be preferable. This is the first report of treating Gram-negative bacteremias with once-daily tigecycline.